Oxford Biomedica Solutions
Jonathan Lee is an experienced quality control professional currently serving as a Senior Quality Control Analyst II at Oxford Biomedica since April 2023. Prior to this role, Jonathan held the position of Senior Quality Control Analyst at Oxford Biomedica Solutions from August 2022 to April 2023. Jonathan's career includes notable positions at Catalent Pharma Solutions as a Quality Control Analyst III and II from February 2021 to August 2022, as well as experience at Acorda Therapeutics, Inc. where positions ranged from Quality Control Analyst I to II over a span from January 2015 to February 2021. Jonathan began the career with a co-op role in Analytical Development/Quality Control at Acorda Therapeutics, Inc. in early 2015. Jonathan holds a Bachelor of Science degree from Northeastern University, earned in December 2015, after completing education at Milford High School from 2007 to 2011.
Oxford Biomedica Solutions
Oxford Biomedica Solutions, LLC is the high-performing, full scope Adeno-Associated Virus (AAV) vector Manufacturing and Innovation joint venture of Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), and Homology Medicines, Inc. (Nasdaq: FIXX) (“Homology”). We offer global pharmaceutical and biotechnology clients innovative manufacturing expertise in AAV and lentiviral-based cell and gene therapies. Oxford Biomedica Solutions LLC provides access to Homology’s innovative and proven end-to-end AAV manufacturing capabilities, and customers also benefit from technical synergies brought in by the Group’s know-how in lentiviral vector manufacturing. This collaborative and complementary vector-based approach has the potential to accelerate our collective mission to improve patients’ lives worldwide.